STUDY DESIGN OF INTRAVENOUS EFGARTIGIMOD IN JUVENILE GENERALIZED MYASTHENIA GRAVIS

被引：0
|
作者：
Kuntz, Nancy L. [1 ]
Bogatyreva, Anna [2 ]
Podhorna, Jana [2 ]
Steeland, Sophie [2 ]
Van Bragt, Tonke [2 ]
Van Hoorick, Benjamin [2 ]
Guglietta, Antonio [2 ]
Howard, James F., Jr. [3 ]
机构：
[1] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Div Neurol, Dept Pediat,Feinberg Sch Med, Chicago, IL USA
[2] argenx, Ghent, Belgium
[3] Univ N Carolina, Chapel Hill, NC USA
来源：
MUSCLE & NERVE | 2022年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S12 / S13
页数：2
相关论文
共 50 条
  • [41] Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center
    Frangiamore, Rita
    Rinaldi, Elena
    Vanoli, Fiammetta
    Andreetta, Francesca
    Ciusani, Emilio
    Bonanno, Silvia
    Maggi, Lorenzo
    Gallone, Annamaria
    Colasuonno, Anna
    Tramacere, Irene
    Cheli, Marta
    Pinna, Alessandro
    Mantegazza, Renato
    Antozzi, Carlo
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (04)
  • [42] A Real-life experience with Eculizumab and Efgartigimod in generalized Myasthenia Gravis patients.
    Sacca, F.
    Pane, C.
    Espinosa, P.
    Sormani, M.
    Signori, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 569 - 570
  • [43] Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration
    Bril, Vera
    Vu, Tuan
    Brauer, Edward
    Kerstens, Rene
    Howard, James
    NEUROLOGY, 2023, 100 (17)
  • [44] REAL-WORLD EXPERIENCE WITH INDIVIDUALIZED DOSING OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
    Silvestri, Nicholas
    MUSCLE & NERVE, 2024, 70 (03) : 638 - 638
  • [45] ADAPT: A PHASE 3 STUDY OF FCRN ANTAGONIST, EFGARTIGIMOD, IN MYASTHENIA GRAVIS
    Howard, James
    Tuan Vu
    Bril, Vera
    De Bleecker, Jan
    Verschuuren, Jan
    Mantegazza, Renato
    Meisel, Andreas
    Peric, Stojan
    de Haard, Hans
    Parys, Wim
    Guglietta, Antonio
    Ulrichts, Peter
    Murai, Hiroyuki
    MUSCLE & NERVE, 2020, 62 : S76 - S76
  • [46] OBSERVED EFFICACY OF EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS ACROSS PATIENT SUBGROUPS IN THE ADAPT-SC plus STUDY
    Muppidi, Srikanth
    Vu, Tuan
    Bhavaraju-Sanka, Ratna
    Brauer, Eddie
    Kerstens, Rene
    Utsugisawa, Kimiaki
    Meisel, Andreas
    MUSCLE & NERVE, 2024, 70 (03) : 703 - 703
  • [47] Efgartigimod improves triple-negative myasthenia gravis
    Frangiamore, Rita
    Rinaldi, Elena
    Vanoli, Fiammetta
    Andreetta, Francesca
    Mantegazza, Renato
    Antozzi, Carlo
    NEUROLOGICAL SCIENCES, 2024, 45 (03) : 1307 - 1309
  • [48] Efgartigimod A novel antibody depletion therapy in myasthenia gravis
    Guidon, Amanda C.
    Juel, Vern C.
    NEUROLOGY, 2019, 92 (23) : 1079 - 1080
  • [49] Juvenile myasthenia gravis
    Papazian, Oscar
    Alfonso, Israel
    Araguez, Nayle
    MEDICINA-BUENOS AIRES, 2009, 69 (01) : 71 - 83
  • [50] Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis
    Sivadasan, Ajith
    Bril, Vera
    IMMUNOTHERAPY, 2023, 15 (08) : 553 - 563
12345